Enzymatica presents COLDPREV study at scientific congress in Copenhagen

Today May 23, 2014, the results from the COLDPREV study on ColdZyme Mouth spray will be presented at the XXXII Congress of the Nordic Association of Otolaryngology in Copenhagen, Denmark. The abstract and poster presentation will be held by Enzymatica’s Executive Vice President of R&D, PhD Mats Clarsund in the congress’ scientific program.

The study which was performed during the spring at the Ear, Nose and Throat Clinic at Skåne University Hospital, shows that ColdZyme Mouth spray reduces both the viral load and the number of sick days with a cold compared with placebo.


- This is our first presentation of the COLDPREV study results in a scientific context. The study confirms what many users already have experineced, namely that the product both prevents colds and reduces the number of days with symtoms. Being able to halve the number of sick days also provide positive economic impacts on society and quality of life for the individual, says Mats Clarsund, EVP Research & Development at Enzymatica.


Study design and result
The COLDPREV study was a randomised, double-blind, placebo-controlled clinical pilot study for the CE-marked medical device ColdZyme® Mouth Spray. In this study 46 subjects, both men and women (aged 20-46), were inoculated (infected) with the common cold virus (rhinovirus) via the nose. Despite the study being a pilot study, aimed at providing a basis for larger studies, a statistically significant difference was found between ColdZyme and placebo with regard to reduction of the viral load in the throat (-99%) and reduction in the number of days with a cold (-54%).

For further information about the COLDPREV study, please contact:
Mats Clarsund, PhD, EVP Research & Development Enzymatica AB (publ)
Phone: +46 733 46 34 29. Email: mats.clarsund@enzymatica.se

For further information about Enzymatica, please contact:
Michael Edelborg Christensen, CEO Enzymatica AB (publ),
Phone: +46 768 14 41 66. Email: michael.christensen@enzymatica.se

About the common cold
The common cold is one of the most commonly occurring infectious diseases. It is caused by viruses that enter the cells via the mucous membranes, principally in the nose, oral cavity and throat. Common symptoms are runny nose, nasal congestion and sore throat. A slight cough and headaches with fever may also form part of the picture, and a cold usually lasts fewer than ten days. People on average have between two and four colds a year. Children are the group that have the most colds, five to ten episodes per year, and frequency falls with age as immunity is built up. The common cold also causes economic costs by increasing short-term sick leave1), while colds are the single largest cause of sick leave, accounting for just over 30% of all absences due to sickness2) .

About the ColdZyme® Mouth Spray
ColdZyme® Mouth Spray is a medical device product, Class 1 (CE marked). The ColdZyme® Mouth Spray reduces the risk of contracting a cold and shortens the sickness duration at an early stage of the infection by creating an active barrier of a thin protecting film in the throat. The active barrier consists primarily of an osmotic agent (glycerol) and enzyme. The enzyme has a unique feature that allows it to be super active at about 37° C, making it superior to break down disease related proteins, countering infection by viruses and bacteria, and promoting healing processes. The product was registered with the Swedish MPA as a medical device in Class I in August 2012 and launched at pharmacies throughout Sweden in September 2013. The product is among the 10 best-selling products in the cold category in Sweden. For more information, visit www.coldzyme.se

About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and registration of medical products based on patented enzyme technology. Enzymatica utilizes a cold-adapted trypsin derived from deep-sea cod. This marine enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. ColdZyme Mouth Spray CE against common cold, was launched in pharmacies throughout Sweden in 2013. For more information, visit www.enzymatica.se.

1 http://www.regeringen.se/sb/d/13804
2 Previa, Press release 2013-04-23